Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors by Keunchil Park, MD, PhD, Daniel Shao Weng Tan, BSc, M.B.B.S., MRCP, Wu-Chou Su, MD, Byoung Chul Cho, MD, PhD, Sang-We Kim, MD, PhD, Ki Hyeong Lee, MD, PhD, Chin-Chou Wang, MD, MS, Takashi Seto, MD, Dennis Chin-Lun Huang, MD, Helen Hayoun Jung, BS, RPh, Ming-Chi Hsu, PhD, Thomas Bogenrieder, MD, PhD, Chia-Chi Lin, MD, PhD

Get full text